// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























387 Abstracts

Predictors for Exacerbating Kidney Function in Patients With Nonvalvular Atrial Fibrillation: The Hokuriku-plus AF Registry

Kenshi Hayashi - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Combined Assessment of Urinary Liver-type Fatty-acid Binding Protein and Plasma B-type Natriuretic Peptide Improves Prediction of Long-term Outcomes in Patients Treated at Medical Cardiac Intensive Care Units

Hiroyuki Naruse - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Microvascular complications of diabetes 1

N/A

Prognostic Value of Von Willebrand Factor in Adult Patients With Congenial Heart Disease

Hideo Ohuchi - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Congenital disorder

Congenital heart disease

N/A

Daily Heart Rate Dynamics and QRS Duration Are Associates With Hemodynamics and Predict All-cause Mortality in Patients After Fontan Operation

Dai Suzuki - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Atrial Fibrillation is Associated With Impaired Exercise Capacity and Adverse Prognosis in Heart Failure Patients With Mid-range Ejection Fraction

Yu Sato - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Prognostic Significance of Peripheral Artery Disease in Heart Failure With Preserved Left Ventricular Ejection Fraction

Koichiro Fujisue - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Angiology

Peripheral artery disease

N/A

Development of a Risk Score for Incident Latent Heart Failure in a Japanese General Population: The Suita Study

Yoshihiro Kokubo - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Prognostic Factors in Heart Failure Patients With Cardiac Cachexia

Yu Sato - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Which Factors Are Correlated With One-Year Preserved Renal Function in Acute Heart Failure Patients With Preserved Ejection Fraction? - Insights From PURSUIT-HFpEF Registry

Kyosuke Yanagawa - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

AMINO ACIDS KYNURENINE AND QUINOLINIC ACID AND TARGET ORGAN DAMAGE IN HYPERTENSIVE PATIENTS – NOVEL INSIGHTS FROM THE STYRIAN HYPERTENSION STUDY

Verheyen, N - European Meeting on Hypertension and Cardiovascular Protection (ESH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

HIGH SYSTOLIC BLOOD PRESSURE IS ASSOCIATED WITH INCIDENT LATENT HEART FAILURE ( THE SUITA STUDY )

Kokubo, Y - European Meeting on Hypertension and Cardiovascular Protection (ESH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

INFLAMMATION RESOLUTION MEDIATORS IN ACUTE HEART FAILURE

Reina-Couto, M - European Meeting on Hypertension and Cardiovascular Protection (ESH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

THE TRADITIONAL CARDIOVASCULAR RISK FACTORS ASSOCIATED WITH INCIDENT LATENT HEART FAILURE IN A GENERAL JAPANESE POPULATION

Kokubo, Y - European Meeting on Hypertension and Cardiovascular Protection (ESH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

N/A

Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction - VICTORIA

Paul Wayne Armstrong - American College of Cardiology (ACC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Heart failure with reduced ejection fraction

Vericiguat

Natriuretic Peptide-Based Inclusion Criteria in COMMANDER-HF Trial

Cunningham JW - American College of Cardiology (ACC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

rivaroxaban

Variability of CMR Tissue Characterization to Identify Cardiotoxicity

Altaha MA - American College of Cardiology (ACC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiotoxicity

N/A

Decongestion and Kidney Function Declines

McCallum W - American College of Cardiology (ACC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

vasopressin Injection

Dietary Patterns and Subclinical Cardiac Injury

Juraschek SP - American College of Cardiology (ACC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronary Artery Disease

N/A

ARNI Based on HF History and Use of Angiotensin Antagonists

Ambrosy AP - American College of Cardiology (ACC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hyperkalemia

Angiotensin II

D-dimmer is a Predictor of Cancer Therapeutics-related Cardiac Dysfunction in Patients Treated With Cardiotoxic Chemotherapy

Masayoshi Oikawa - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Congestive heart failure

L-Tyrosine

Copyright © 2026. QuantiNova All rights reserved